Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis

被引：27

作者：

Russell, Anthony ^{[2
]}

Beresniak, Ariel ^{[1
,3
]}

Bessette, Louis ^{[4
]}

Haraoui, Boulos ^{[5
]}

Rahman, Proton ^{[6
]}

Thorne, Carter ^{[7
]}

Maclean, Ross ^{[8
]}

Dupont, Danielle ^{[9
]}

机构：

[1] Paris Descartes Univ, LIRAES, Paris, France

[2] Univ Alberta, Edmonton, AB, Canada

[3] Data Min Int, Geneva, Switzerland

[4] CHU Laval, Quebec City, PQ G1V 4G2, Canada

[5] Univ Montreal, Montreal, PQ, Canada

[6] St Clares Mercy Hosp, St John, NF, Canada

[7] Univ Toronto, Southlake Reg Hlth Ctr, Toronto, ON, Canada

[8] Bristol Myers Squibb Co, Outcomes Res, Princeton, NJ USA

[9] Bristol Myers Squibb Int Corp, Braine Lalleud, Belgium

来源：

CLINICAL RHEUMATOLOGY | 2009年 / 28卷 / 04期

关键词：

Abatacept; Anti-TNF therapy; Cost-effectiveness; Modeling; Rheumatoid Arthritis; TUMOR-NECROSIS-FACTOR; COSTIMULATION MODULATOR ABATACEPT; FACTOR-BLOCKING-AGENTS; DISEASE-ACTIVITY; ECONOMIC-EVALUATION; EULAR RESPONSE; DOUBLE-BLIND; INFLIXIMAB; METHOTREXATE; ETANERCEPT;

D O I：

10.1007/s10067-008-1060-4

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

To assess the cost-effectiveness of abatacept compared to different biologic treatment strategies for moderate to severe rheumatoid arthritis based on current medical practices in Canada. A model was constructed to assess the cost-effectiveness of various biologic treatments over a 2-year time horizon, using two effectiveness endpoints: "low disease activity state" (LDAS) and "remission". Abatacept, as first biologic agent after an inadequate response to DMARDs, provides greater treatment success rate for achieving LDAS (29.4% versus 15.6%) and remission (14.8% versus 5.2%), and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p < 0.001). Abatacept, as second biologic agent after an inadequate response to one anti-TNF agent, provides greater treatment success rate for achieving LDAS (17.1% versus 10.2%) and remission (7.4% versus 3.9%) and appears significantly more cost-effective compared to the sequential use of anti-TNF agents (p < 0.001). Abatacept is a cost-effective strategy in patients with an inadequate response to DMARDs or to one anti-TNF agent.

引用

页码：403 / 412

页数：10

共 50 条

[1] Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis
Anthony Russell
Ariel Beresniak
Louis Bessette
Boulos Haraoui
Proton Rahman
Carter Thorne
Ross Maclean
Danielle Dupont
[J]. Clinical Rheumatology, 2009, 28
[2] Cost-effectiveness of abatacept versus other biologic agents in dmards and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis in Canada
Haraoui, B.
Russell, A.
Thorne, C.
[J]. JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1628 - 1628
[3] Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach
Cimmino, M. A.
Leardini, G.
Salaffi, F.
Intorcia, M.
Bellatreccia, A.
Dupont, D.
Beresniak, A.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (04) : 633 - 641
[4] Cost-effectiveness simulation model of abatacept versus anti-TNF treatment strategies in rheumatoid arthritis in France
Saraux, Alain
Goupille, Philippe
Gossec, Laure
Bregman, Bruno
Boccard, Eric
Dupont, Danielle
Beresmak, Ariel
[J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S463 - S463
[5] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
Tsao, Nicole W.
Shojania, Kam
Marra, Carlo A.
[J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
[6] Comparative Effectiveness of Abatacept Versus Subsequent Anti-TNF Agents Among Rheumatoid Arthritis Patients with Previous Anti-TNF Exposure.
Harrold, Leslie R.
Reed, George
Curtis, Jeffrey R.
Solomon, Daniel H.
Hochberg, Marc
Onofrei, Alina U.
Kremer, Joel M.
Greenberg, Jeffrey D.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S1019 - S1019
[7] THE COST-EFFECTIVENESS OF BIOLOGIC DMARDS IN PATIENTS WITH SEVERE OR MILD-TO-SEVERE RHEUMATOID ARTHRITIS AFTER CONVENTIONAL DMARDS
Wailoo, A. J.
Stevenson, M.
Tosh, J.
Hernandez, M.
Stevens, J. W.
Archer, R.
Simpson, E.
Hock, Everson E.
Scott, D.
Young, A.
Paisley, S.
Williams, K.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A380 - A380
[8] Efficacy of abatacept following wash-out of anti-TNF therapy in rheumatoid arthritis patients in the ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate Responders) trial: Current versus prior discontinuation.
Genovese, M
Schiff, M
Luggen, M
Aranda, R
Becker, JC
White, A
Dougados, M
[J]. ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S560 - S561
[9] Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs
Narvaez, J.
Diaz-Torne, C.
Ruiz, J. M.
Hernandez, M. V.
Torrente-Segarra, V.
Ros, S.
Rodriguez de la Serna, A.
Diaz-Lopez, C.
Sanmarti, R.
Nolla, J. M.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2011, 29 (06) : 991 - 997
[10] MODELLING COST-EFFECTIVENESS OF BIOLOGIC STRATEGIES FOR THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN FINLAND
Puolakka, Kari
[J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2010, 39 : 34 - 34

← 1 2 3 4 5 →